Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oberon phase III trial of tozorakimab in symptomatic COPD with prior exacerbations
NL-OMON54370Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tozorakimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Rate of moderate to severe COPD exacerbations in former smokers. Started May 2022; status: recruiting.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON54370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54370.